316 related articles for article (PubMed ID: 19390552)
1. Next generation oncology drug development: opportunities and challenges.
Gutierrez ME; Kummar S; Giaccone G
Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
[TBL] [Abstract][Full Text] [Related]
2. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
4. Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
Thall PF; Garrett-Mayer E; Wages NA; Halabi S; Cheung YK
Clin Trials; 2024 Jun; 21(3):267-272. PubMed ID: 38570906
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C; Lee JJ; Siu LL
J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the doses of cancer drugs after usual dose finding.
Strohbehn GW; Stadler WM; Boonstra PS; Ratain MJ
Clin Trials; 2024 Jun; 21(3):340-349. PubMed ID: 38148731
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of adaptive trial designs for dose optimization.
Zhang J; Chen X; Li B; Yan F
Pharm Stat; 2023; 22(5):797-814. PubMed ID: 37156731
[TBL] [Abstract][Full Text] [Related]
9. [Introduction of Oncology Dose-Finding Trial Designs].
Takeda K
Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial designs for targeted agents.
Ma BB; Britten CD; Siu LL
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1287-305. PubMed ID: 12512393
[TBL] [Abstract][Full Text] [Related]
11. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
Bullock JM; Rahman A; Liu Q
Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
[TBL] [Abstract][Full Text] [Related]
12. Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
Zang Y; Lee JJ; Yuan Y
Clin Trials; 2014 Jun; 11(3):319-327. PubMed ID: 24844841
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
Ji Y; Jin JY; Hyman DM; Kim G; Suri A
Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
[No Abstract] [Full Text] [Related]
14. The changing landscape of phase I trials in oncology.
Wong KM; Capasso A; Eckhardt SG
Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
[TBL] [Abstract][Full Text] [Related]
15. Oncology trial design: More accurately and efficiently advancing the field.
Hohl RJ
Clin Pharmacol Ther; 2015 May; 97(5):430-2. PubMed ID: 25684240
[No Abstract] [Full Text] [Related]
16. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
17. Reprioritizing Risk and Benefit: The Future of Study Design in Early-Phase Cancer Research.
Sisk BA; Dubois J; Hobbs BP; Kodish E
Ethics Hum Res; 2019 Nov; 41(6):2-11. PubMed ID: 31743629
[TBL] [Abstract][Full Text] [Related]
18. Dose optimization for cancer treatments with considerations for late-onset toxicities.
Biard L; Andrillon A; Silva RB; Lee SM
Clin Trials; 2024 Jun; 21(3):322-330. PubMed ID: 38591582
[TBL] [Abstract][Full Text] [Related]
19. An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.
Colin P; Delattre M; Minini P; Micallef S
J Biopharm Stat; 2017; 27(6):1054-1072. PubMed ID: 28375746
[TBL] [Abstract][Full Text] [Related]
20. An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.
Jessen BA; Cornwell P; Redmond S; Visalli T; Lemper M; Bunch T; Hart T
Cancer Chemother Pharmacol; 2023 Dec; 92(6):455-464. PubMed ID: 37505272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
